Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 17%
Buy 44%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is a leading medical device company with a strong product pipeline that is expected to drive revenue growth and margin improvement. However, inconsistent execution and quarterly results may limit the company's potential for P/E multiple expansion. Upside drivers include better than expected sales of new products, better margins, and positive currency impacts. Risks include loss of market share to competitors and disappointing sales from new products. With the recent acquisition of Scientia Vascular, Medtronic may be poised for significant earnings growth in the future.

Bears say

Medtronic is expected to face risks such as market share loss to competitors, underwhelming sales from new products and negative currency impacts. The company's bear case scenario includes a growth slowdown of <5% due to unsuccessful new product launches and market share loss, resulting in a below-consensus earnings that corresponds to ~$76 per share. In contrast, the base case scenario predicts revenue growth in the range of 5-7%, driven by the company's new product pipeline and improved operating margins, resulting in moderately above-consensus earnings. However, there are still risks to the company's target, including market share loss to competitors, underwhelming sales from new products and negative currency impacts.

Medtronic (MDT) has been analyzed by 18 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 44% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 18 analysts, Medtronic (MDT) has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.